Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in clinical and commercial production of cell and gene therapies, has broken ground on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located at Providence Park in College Station, Texas. [Read more…]

SEATTLE, March 2, 2021 — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities. [Read more…]

FLORHAM PARK, N.J., March 18, 2021 — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the company has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme (GBM). CYNK-001 is currently being investigated in multiple clinical trials, including a Phase 1 clinical trial for GBM. [Read more…]

Celonic to Boost Its Cell and Gene Therapy (CGT) Production with a Facility in the Upcoming Life Science Parket Rheintal, located in Stein, Switzerland.

Celonic Group, a leading global CDMO specializing in the development and production of Advanced Therapy Medicinal Products (ATMP) and bio-therapeutics, announced a long-term lease agreement for a new production site and office space. The facility will span 91,500 square feet (8,500 sqm) in the WST-222 building at the Novartis-operated Life Science Park Rheintal. [Read more…]